Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Pharma companies need to move beyond the “weight-loss Olympics” and focus on more durable treatments with fewer side effects, ...

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla ...

Novo Nordisk has approached the Delhi High Court to prevent Dr Reddy’s Laboratories from manufacturing and exporting ...

Eli Lilly (LLY) stock rises as analysts cheer Phase 3 trial data for the company's next-gen weight loss therapy, retatrutide.

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.